CorMedix Inc (CRMD) concluded trading on Thursday at a closing price of $6.39, with 2.62 million shares of worth about $16.76 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 79.49% during that period and on April 11, 2024 the price saw a gain of about 21.02%. Currently the company’s common shares owned by public are about 54.94M shares, out of which, 53.86M shares are available for trading.
Stock saw a price change of 43.27% in past 5 days and over the past one month there was a price change of 86.84%. Year-to-date (YTD), CRMD shares are showing a performance of 69.95% which increased to 27.04% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.57 but also hit the highest price of $6.09 during that period. The average intraday trading volume for CorMedix Inc shares is 460.33K. The stock is currently trading 52.02% above its 20-day simple moving average (SMA20), while that difference is up 74.50% for SMA50 and it goes to 73.17% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CorMedix Inc (NASDAQ: CRMD) currently have 54.94M outstanding shares and institutions hold larger chunk of about 33.84% of that.
The stock has a current market capitalization of $351.32M and its 3Y-monthly beta is at 1.84. It has posted earnings per share of -$0.92 in the same period. It has Quick Ratio of 6.78 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRMD, volatility over the week remained 11.32% while standing at 6.95% over the month.
Stock’s fiscal year EPS is expected to rise by 18.55% while it is estimated to increase by 87.21% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by RBC Capital Mkts on August 10, 2023 offering an Outperform rating for the stock and assigned a target price of $6 to it. Coverage by Needham stated CorMedix Inc (CRMD) stock as a Buy in their note to investors on February 17, 2021, suggesting a price target of $31 for the stock. On September 29, 2020, JMP Securities Initiated their recommendations, while on September 21, 2020, Truist Initiated their ratings for the stock with a price target of $20. Stock get a Buy rating from B. Riley FBR on December 18, 2019.
